SCHEMBL480988

SCHEMBL480988

COC(=O)c1cccc(Cc2ccc(CI)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.60
CYP4F2 P78329 2/20 0.59
CYP4A11 Q02928 2/20 0.59
SLC7A5 Q01650 1/20 0.52
MRGPRX4 Q96LA9 2/20 0.49
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPT P10636 2/20 0.48
HIF1A Q16665 1/20 0.47
MPO P05164 1/20 0.46
FOLH1 Q04609 1/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 3/20 0.45
TSHR P16473 2/20 0.45
GAA P10253 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481109 0.92 LOXL2 (0.62) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL4446686 0.89 LOXL2 (0.70) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL481205 0.88 LOXL2 (0.54) LOXL2CYP4F2CYP4A11ALDH1A1RAB9A
SCHEMBL2069334 0.87 LOXL2 (0.68) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL9829957 0.86 LOXL2 (0.62) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL481432 0.86 CYP4F2 (0.65) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL2515139 0.85 LOXL2 (0.60) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL481090 0.84 LOXL2 (0.59) LOXL2CYP4F2CYP4A11ALDH1A1SMN1; SMN2
SCHEMBL8716270 0.82 LOXL2 (0.60) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL481481 0.81 CYP4F2 (0.67) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 LOXL2 3193/4885CYP4F2 838/4885CYP4A11 1356/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 LOXL2 2583/4885CYP4F2 1546/4885CYP4A11 1088/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 LOXL2 2583/4885CYP4F2 1546/4885CYP4A11 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.